Search results
HanxBio announces the publication of a research paper in Scientific Reports on preclinical...
KOLR - KSFX Ozarks· 2 days agoHanxBio today announced that it has published a research article titled "Narazaciclib, a novel...
Deverra Therapeutics Granted FDA Fast Track Designation for DVX101
Digital Journal· 5 hours agoDesignation Validates Preliminary Data and Supports Accelerated Drug Development SEATTLE, WA / ACCESSWIRE / April 24, 2024 / Deverra Therapeutics, Inc., a clinical-stage biotechnology company ...
CAR-T Plus Stem-Cell Transplant Promising for CD7+ Blood Cancers
MedPage Today· 21 hours agoA strategy of sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and haploidentical...
Potential new treatment strategy for aggressive leukemia
Medical Xpress· 6 days agoIn findings published in Nature Cancer, researchers reveal that blocking these oxygen-sensing enzymes can significantly halt acute myeloid leukemia ...
...Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute ...
Morningstar· 7 days ago“We are delighted to safely progress through the second, higher dose cohort to reach an important study milestone for the United States Food and Drug Administration...
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest...
WMBD - FOX 43 Peoria· 56 minutes agoAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results ...
Moleculin's acute myeloid leukemia treatment gets EMA's orphan drug designation
Seeking Alpha· 7 days agoMoleculin Biotech's Annamycin receives Orphan Drug Designation from the European Medicines Agency for AML treatment, expanding its potential market reach.
Central Mass. by the Numbers
Gannett via AOL· 4 days agoDavis' son, Larry, said the cause was acute myeloid leukemia. Davis and his sons, Larry and Doug, developed the idea of a petting zoo ...
FDA grants breakthrough status for Kura Oncology's AML drug candicate By Investing.com
Investing.com· 3 days agoFood and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to its drug...
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute ...
NBC 17 Raleigh· 7 days ago– Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML subjects ...